Effect of early administration of tolvaptan on pleural effusion post-hepatectomy.
Hepatectomy
Pleural effusion
Post-hepatectomy liver failure
Saturation of percutaneous oxygen
Tolvaptan
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
16 Oct 2023
16 Oct 2023
Historique:
received:
13
03
2023
accepted:
04
10
2023
medline:
1
11
2023
pubmed:
17
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
This study evaluated the efficacy of tolvaptan administration at the early stage after hepatectomy to control pleural effusion and improve the postoperative course. Patients were administered tolvaptan (7.5 mg) and spironolactone (25 mg) from postoperative day 1 to postoperative day 5 (tolvaptan group, n = 68) for 13 months. Early administration of tolvaptan was not provided in the control group (n = 68); however, diuretics were appropriately administered according to the patient's condition. The amount of pleural effusion on computed tomography on postoperative day 5 was compared between the two groups. The amount of pleural effusion and increase in body weight on postoperative day 5 showed significant differences in both groups (p < 0.001 and p = 0.019, respectively). However, the rate of pleural aspiration and the duration of postoperative hospitalization were comparable between the groups. The amount of intraoperative blood loss and lack of early administration of tolvaptan were identified as independent risk factors contributing to pleural effusion on multivariate analysis. Early administration of tolvaptan to patients after hepatectomy was found to be capable of controlling postoperative pleural effusion and increase in body weight, but it did not reduce the rate of pleural aspiration or the hospitalization period.
Identifiants
pubmed: 37845430
doi: 10.1007/s00423-023-03136-4
pii: 10.1007/s00423-023-03136-4
doi:
Substances chimiques
Tolvaptan
21G72T1950
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
406Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Wei AC, Tung-Ping Poon R, Fan ST, Wong J (2003) Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 90(1):33–41. https://doi.org/10.1002/bjs.4018
doi: 10.1002/bjs.4018
pubmed: 12520572
Uchiyama H, Harimoto N, Itoh S, Yoshizumi T, Ikegami T, Maehara Y (2017) Pleural effusion after hepatectomy for hepatocellular carcinoma: risk factor analyses and its impact on oncological outcomes. World J Surg 41(4):1089–1099. https://doi.org/10.1007/s00268-016-3826-1
doi: 10.1007/s00268-016-3826-1
pubmed: 27882419
Yakar T, Demir M, Dogan O, Parlakgumus A, Ozer B, Serin E (2016) High Dose oral furosemide with salt ingestion in the treatment of refractory ascites of liver cirrhosis. Clin Invest Med 39(6):27502
doi: 10.25011/cim.v39i6.27502
pubmed: 27917793
Takahara T, Wakabayashi G, Beppu T, Aihara A, Hasegawa K, Gotohda N, Hatano E, Tanahashi Y, Mizuguchi T, Kamiyama T, Ikeda T, Tanaka S, Taniai N, Baba H, Tanabe M, Kokudo N, Konishi M, Uemoto S, Sugioka A, Hirata K, Taketomi A, Maehara Y, Kubo S, Uchida E, Miyata H, Nakamura M, Kaneko H, Yamaue H, Miyazaki M, Takada T (2015) Long-term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 22(10):721–727. https://doi.org/10.1002/jhbp.276
doi: 10.1002/jhbp.276
pubmed: 26096910
Yan JJ, Zhang XH, Chu KJ, Huang L, Zhou FG, Yan YQ (2005) Prevention and management of pleural effusion following hepatectomy in primary liver cancer. Hepatobiliary Pancreat Dis Int 4(3):375–378
pubmed: 16109519
Ikegami T, Shimada M, Imura S, Nakamura T, Kawahito S, Morine Y, Kanemura H, Hanaoka J (2009) Argon gas embolism in the application of laparoscopic microwave coagulation therapy. J Hepatobiliary Pancreat Surg 16(3):394–398. https://doi.org/10.1007/s00534-008-0039-5
doi: 10.1007/s00534-008-0039-5
pubmed: 19209380
Iwamoto T, Maeda M, Saeki I, Hidaka I, Tajima K, Ishikawa T, Takami T, Sakaida I (2019) Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites. J Gastroenterol Hepatol 34(7):1231–1235. https://doi.org/10.1111/jgh.14524
doi: 10.1111/jgh.14524
pubmed: 30370940
Okita K, Kawazoe S, Hasebe C, Kajimura K, Kaneko A, Okada M, Sakaida I (2014) Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial. Hepatol Res 44(1):83–91. https://doi.org/10.1111/hepr.12099
doi: 10.1111/hepr.12099
pubmed: 23530991
Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, Okada M, Okita K (2014) Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 44(1):73–82. https://doi.org/10.1111/hepr.12098
doi: 10.1111/hepr.12098
pubmed: 23551935
Chen H, Jiang W, Li X, Meng Z, Chen H, Li J, Wang J, Zhao X (2020) Efficacy of tolvaptan for fluid management after cardiovascular surgery: a systematic review and meta-analysis of randomized control trials. Exp Ther Med 20(3):2585–2592. https://doi.org/10.3892/etm.2020.9007
doi: 10.3892/etm.2020.9007
pubmed: 32765752
pmcid: 7401488
Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, Fan ST, Yokoyama Y, Crawford M, Makuuchi M, Christophi C, Banting S, Brooke-Smith M, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Nimura Y, Figueras J, DeMatteo RP, Büchler MW, Weitz J (2011) Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery 149(5):680–688. https://doi.org/10.1016/j.surg.2010.12.002
doi: 10.1016/j.surg.2010.12.002
pubmed: 21316725
Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo RP, Christophi C, Banting S, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Yokoyama Y, Fan ST, Nimura Y, Figueras J, Capussotti L, Büchler MW, Weitz J (2011) Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 149(5):713–724. https://doi.org/10.1016/j.surg.2010.10.001
doi: 10.1016/j.surg.2010.10.001
pubmed: 21236455
Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, Reinke CE, Morgan S, Solomkin JS, Mazuski JE, Dellinger EP, Itani KMF, Berbari EF, Segreti J, Parvizi J, Blanchard J, Allen G, Kluytmans J, Donlan R (2017) Schecter WP (2017) Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection. JAMA Surg 152(8):784–791. https://doi.org/10.1001/jamasurg.2017.0904
doi: 10.1001/jamasurg.2017.0904
pubmed: 28467526
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196. https://doi.org/10.1097/SLA.0b013e3181b13ca2
doi: 10.1097/SLA.0b013e3181b13ca2
pubmed: 19638912
Sakaida I, Terai S, Kurosaki M, Okada M, Hirano T, Fukuta Y (2020) Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). J Gastroenterol 55(8):800–810. https://doi.org/10.1007/s00535-020-01691-x
doi: 10.1007/s00535-020-01691-x
pubmed: 32388692
pmcid: 7376514
Ginès P, Guevara M (2008) Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 48(3):1002–1010. https://doi.org/10.1002/hep.22418
doi: 10.1002/hep.22418
pubmed: 18671303
Runyon BA (2009) Management of adult patients with ascites due to cirrhosis: an update. Hepatology 49(6):2087–2107. https://doi.org/10.1002/hep.22853
doi: 10.1002/hep.22853
pubmed: 19475696
European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53(3):397–417. https://doi.org/10.1016/j.jhep.2010.05.004
doi: 10.1016/j.jhep.2010.05.004
Sakaida I, Terai S, Kurosaki M, Yasuda M, Okada M, Bando K, Fukuta Y (2017) Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study). Hepatol Res 47(11):1137–1146. https://doi.org/10.1111/hepr.12852
doi: 10.1111/hepr.12852
pubmed: 27958663
Kinugawa K, Sato N, Inomata T, Yasuda M, Shibasaki Y, Shimakawa T (2018) Novel risk score efficiently prevents tolvaptan-induced hypernatremic events in patients with heart failure. Circ J 82(5):1344–1350. https://doi.org/10.1253/circj.CJ-17-0986
doi: 10.1253/circj.CJ-17-0986
pubmed: 29607892
Kishimoto Y, Nakamura Y, Harada S, Onohara T, Kishimoto S, Kurashiki T, Fujiwara Y, Nishimura M (2018) Can Tolvaptan protect renal function in the early postoperative period of cardiac surgery? - results of a single-center randomized controlled study. Circ J 82(4):999–1007. https://doi.org/10.1253/circj.CJ-17-0967
doi: 10.1253/circj.CJ-17-0967
pubmed: 29467353
Matsuyama K, Koizumi N, Nishibe T, Iwasaki T, Iwahasi T, Toguchi K, Takahashi S, Iwahori A, Maruno K, Ogino H (2016) Effects of short-term administration of tolvaptan after open heart surgery. Int J Cardiol 220:192–195. https://doi.org/10.1016/j.ijcard.2016.06.156
doi: 10.1016/j.ijcard.2016.06.156
pubmed: 27379922
Kato TS, Nakamura H, Murata M, Kuroda K, Suzuki H, Yokoyama Y, Shimada A, Matsushita S, Yamamoto T, Amano A (2016) The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery. BMC Cardiovasc Disord 16(1):181. https://doi.org/10.1186/s12872-016-0341-0
doi: 10.1186/s12872-016-0341-0
pubmed: 27624603
pmcid: 5022266
Suehiro Y, Hosono M, Shibata T, Sasaki Y, Hirai H, Nakahira A, Kubota Y, Kaku D, Suehiro S (2016) Efficacy and safety evaluation of Tolvaptan on management of fluid balance after cardiovascular surgery using cardiopulmonary bypass. Osaka City Med J 62(2):111–119
pubmed: 30721586
Uojima H, Hidaka H, Tanaka Y, Wada N, Kubota K, Nakazawa T, Shibuya A, Sung JH, Kako M, Koizumi W (2020) Furosemide dose changes associated with furosemide/tolvaptan combination therapy in patients with cirrhosis. Dig Dis 38(1):38–45. https://doi.org/10.1159/000501267
doi: 10.1159/000501267
pubmed: 31216537
Iida H, Maehira H, Mori H, Maekawa T, Tani M (2020) Post-hepatectomy tolvaptan-induced hypernatremia in a hepatocellular carcinoma patient with cirrhosis: a case report. Surg Case Rep 6(1):61. https://doi.org/10.1186/s40792-020-00825-w
doi: 10.1186/s40792-020-00825-w
pubmed: 32232601
pmcid: 7105548
Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, Mizuguchi K (2015) Effectiveness and adverse events of tolvaptan in octogenarians with heart failure Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study). Int Heart J. 56(2):137–143. https://doi.org/10.1536/ihj.14-332
doi: 10.1536/ihj.14-332
pubmed: 25740389
Hirai K, Shimomura T, Moriwaki H, Ishii H, Shimoshikiryo T, Tsuji D, Inoue K, Kadoiri T, Itoh K (2016) Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment. Eur J Clin Pharmacol 72(10):1177–1183. https://doi.org/10.1007/s00228-016-2091-4
doi: 10.1007/s00228-016-2091-4
pubmed: 27395406